way with a standard staining used in clinical routine. Others' models did not see any fibrosis 2,3 or unphysiological subcapsular fibrosis just after intraperitoneal virus injection. 4 Other researchers have also described the need for strong "danger signals" to break tolerance against liver antigens 3-5 ; however, we could show that the mere overexpression of the autoantigen is not sufficient to cause AIH. This is well in line with the experience of Lapierre et al. employing a repeated prime boost protocol with DNA vaccination with a plasmid encoding for a secreted chimeric antigen of cytochrome P4502D6 (CYP2D6) and formiminotransferase cyclodeaminase (FTCD), with the addition interleukin (IL)-12 2 or expression with an adenovirus. 3 Of note, we have also tested intramuscular DNA injection with cytomegalovirus-promoter-driven FTCD and IL-12, but did not see meaningful AIH within 6 months in NOD mice (see Fig. 1).The important publication by Bowen et al. 6 did not use danger signals, but rather induced a self-limited hepatitis, followed by immune tolerance, thereby, rather supporting our statement.Regarding the nature of the inducing autoantigen, we could show that similar antigens can induce AIH as well as identical antigens. However, we did not try CYP2D6 as an orthologous autoantigen. The amount of virus could be excluded as a variable, because we tried 1 3 10 9 to 1 3 10 10 plaque-forming units of our adenovirus, as reported by Holdener et al. 4 As recently discussed, 7 we think that all the mentioned models are important and can be used to explain various aspects of AIH and hepatic immune tolerance.